Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 15/20 | 0.39 |
| ▸ | CA2 | P00918 | 14/20 | 0.39 |
| ▸ | CA12 | O43570 | 13/20 | 0.39 |
| ▸ | CA9 | Q16790 | 12/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517591 | 0.81 | TDP1 (0.51) | ALDH1A1TDP1CA1CA2CA12 | |
| SCHEMBL21589347 | 0.81 | LMNA (0.48) | ALDH1A1TDP1CA1CA2CA12 | |
| SCHEMBL28201480 | 0.79 | CA1 (0.61) | CA1CA2CA12CA9CA7 | |
| SCHEMBL29182471 | 0.76 | CA1 (0.45) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL19618274 | 0.76 | ALDH1A1 (0.48) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL651902 | 0.74 | ALDH1A1 (0.71) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| Sulfuric Acid SCHEMBL9450963 | 0.72 | ALDH1A1 (0.57) | ALDH1A1HSD17B10CA1CA2CA12 | |
| SCHEMBL12113370 | 0.72 | KMT2A (0.54) | CA1CA2CA12CA9PRMT1 | |
| SCHEMBL460563 | 0.71 | ALDH1A1 (0.48) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL20998325 | 0.71 | ALDH1A1 (0.48) | ALDH1A1HSD17B10TDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079833-A1 | BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS | ALUMEND, LLC (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079833-A1 | BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS | SUN2, BMP2, TAGLN2 | ALDH1A1 1539/4885HSD17B10 2647/4885TDP1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.